Amylyx Pharmaceuticals, Inc. (AMLX)
34.74
-2.44
(-6.56%)
USD |
NASDAQ |
Aug 28, 16:00
35.42
+0.68
(+1.96%)
After-Hours: 20:00
Amylyx Pharmaceuticals Free Cash Flow : -130.72M for June 30, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -130.72M |
| March 31, 2026 | -124.53M |
| December 31, 2025 | -123.48M |
| September 30, 2025 | -154.52M |
| June 30, 2025 | -201.88M |
| March 31, 2025 | -243.29M |
| December 31, 2024 | -204.01M |
| September 30, 2024 | -131.78M |
| June 30, 2024 | -59.56M |
| March 31, 2024 | 15.44M |
| Date | Value |
|---|---|
| December 31, 2023 | 10.68M |
| September 30, 2023 | -52.83M |
| June 30, 2023 | -90.84M |
| March 31, 2023 | -146.74M |
| December 31, 2022 | -182.40M |
| September 30, 2022 | -160.51M |
| June 30, 2022 | -137.99M |
| March 31, 2022 | -103.47M |
| December 31, 2021 | -75.15M |
| September 30, 2021 | -55.76M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Pfizer Inc. | 10.99B |
| Eli Lilly & Co. | 13.56B |
| Merck & Co., Inc. | 16.06B |
| EyePoint, Inc. | -271.28M |
| Bristol Myers Squibb Co. | 11.44B |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -31.42M |
| Cash from Investing (Quarterly) | -149.80M |
| Cash from Financing (Quarterly) | 1.479M |
| Free Cash Flow Per Share (Quarterly) | -0.2829 |
| Free Cash Flow to Equity (Quarterly) | -31.08M |
| Free Cash Flow to Firm (Quarterly) | -31.45M |
| Free Cash Flow Yield | -3.54% |